Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Clinical applications of PD-L1 bioassays for cancer immunotherapy
Delong Liu, Shuhang Wang, Wendy Bindeman
Journal of Hematology & Oncology (2017) Vol. 10, Iss. 1
Open Access | Times Cited: 77

Showing 1-25 of 77 citing articles:

Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors
Ming Yi, Dechao Jiao, Hanxiao Xu, et al.
Molecular Cancer (2018) Vol. 17, Iss. 1
Open Access | Times Cited: 670
Immune checkpoint inhibitors of PD-L1 as cancer therapeutics
Akintunde Akinleye, Zoaib Rasool
Journal of Hematology & Oncology (2019) Vol. 12, Iss. 1
Open Access | Times Cited: 622
Anti-PD-1 Antibody SHR-1210 Combined with Apatinib for Advanced Hepatocellular Carcinoma, Gastric, or Esophagogastric Junction Cancer: An Open-label, Dose Escalation and Expansion Study
Jian-Ming Xu, Yun Zhang, Ru Jia, et al.
Clinical Cancer Research (2018) Vol. 25, Iss. 2, pp. 515-523
Open Access | Times Cited: 436
Emerging therapies for small cell lung cancer
Sen Yang, Zhe Zhang, Qiming Wang
Journal of Hematology & Oncology (2019) Vol. 12, Iss. 1
Open Access | Times Cited: 351
Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study
Luana Calabrò, Aldo Morra, Diana Giannarelli, et al.
The Lancet Respiratory Medicine (2018) Vol. 6, Iss. 6, pp. 451-460
Closed Access | Times Cited: 202
Activity of pembrolizumab in relapsed/refractory NK/T-cell lymphoma
Xin Li, Yasong Cheng, Mingzhi Zhang, et al.
Journal of Hematology & Oncology (2018) Vol. 11, Iss. 1
Open Access | Times Cited: 180
Tumor immune escape: extracellular vesicles roles and therapeutics application
Mahdi Ahmadi, Reza Abbasi, Jafar Rezaie
Cell Communication and Signaling (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 28
Gut microbiome modulates efficacy of immune checkpoint inhibitors
Ming Yi, Shengnan Yu, Shuang Qin, et al.
Journal of Hematology & Oncology (2018) Vol. 11, Iss. 1
Open Access | Times Cited: 161
Dynamic change of PD-L1 expression on circulating tumor cells in advanced solid tumor patients undergoing PD-1 blockade therapy
Chunyan Yue, Yubo Jiang, Ping Li, et al.
OncoImmunology (2018) Vol. 7, Iss. 7, pp. e1438111-e1438111
Open Access | Times Cited: 137
PD-1 blockade in advanced NSCLC: A focus on pembrolizumab
Solange Peters, Keith M. Kerr, Rolf A. Stahel
Cancer Treatment Reviews (2017) Vol. 62, pp. 39-49
Open Access | Times Cited: 126
Prospects for combining immune checkpoint blockade with PARP inhibition
Anping Li, Ming Yi, Shuang Qin, et al.
Journal of Hematology & Oncology (2019) Vol. 12, Iss. 1
Open Access | Times Cited: 120
The role of neoantigen in immune checkpoint blockade therapy
Ming Yi, Shuang Qin, Weiheng Zhao, et al.
Experimental Hematology and Oncology (2018) Vol. 7, Iss. 1
Open Access | Times Cited: 119
Emerging therapies in advanced hepatocellular carcinoma
Sowmini Medavaram, Yue Zhang
Experimental Hematology and Oncology (2018) Vol. 7, Iss. 1
Open Access | Times Cited: 110
A phase I study of the PD-L1 inhibitor, durvalumab, in combination with a PARP inhibitor, olaparib, and a VEGFR1–3 inhibitor, cediranib, in recurrent women’s cancers with biomarker analyses
Alexandra S. Zimmer, E. Hitt Nichols, Ashley Cimino‐Mathews, et al.
Journal for ImmunoTherapy of Cancer (2019) Vol. 7, Iss. 1
Open Access | Times Cited: 102
Challenges for immunotherapy for the treatment of platinum resistant ovarian cancer
Olivia Le Saux, Isabelle Ray‐Coquard, Sana Intidhar Labidi‐Galy
Seminars in Cancer Biology (2020) Vol. 77, pp. 127-143
Open Access | Times Cited: 99
PD-1/PD-L blockade in gastrointestinal cancers: lessons learned and the road toward precision immunotherapy
Junyu Long, Jianzhen Lin, Anqiang Wang, et al.
Journal of Hematology & Oncology (2017) Vol. 10, Iss. 1
Open Access | Times Cited: 96
The evolving role of PD-L1 testing in patients with metastatic urothelial carcinoma
Thomas Powles, Jill Walker, J. Andrew Williams, et al.
Cancer Treatment Reviews (2019) Vol. 82, pp. 101925-101925
Open Access | Times Cited: 90
Small molecule inhibitors against PD-1/PD-L1 immune checkpoints and current methodologies for their development: a review
Chang Liu, Navindra P. Seeram, Hang Ma
Cancer Cell International (2021) Vol. 21, Iss. 1
Open Access | Times Cited: 66
Stem cell membrane-camouflaged targeted delivery system in tumor
Weiyue Zhang, Xin Huang
Materials Today Bio (2022) Vol. 16, pp. 100377-100377
Open Access | Times Cited: 45
A Comprehensive Review of US FDA-Approved Immune Checkpoint Inhibitors in Urothelial Carcinoma
Fu-Shun Hsu, Chun-Hung Su, Kou-How Huang
Journal of Immunology Research (2017) Vol. 2017, pp. 1-9
Open Access | Times Cited: 79
The Biogenesis, Biology, and Clinical Significance of Exosomal PD-L1 in Cancer
Yanyan Tang, Ping Zhang, Yumin Wang, et al.
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 68
PD‐L1 methylation regulates PD‐L1 expression and is associated with melanoma survival
Goran Micevic, Durga Thakral, Meaghan K. McGeary, et al.
Pigment Cell & Melanoma Research (2018) Vol. 32, Iss. 3, pp. 435-440
Open Access | Times Cited: 67
Targeted literature review on use of tumor mutational burden status and programmed cell death ligand 1 expression to predict outcomes of checkpoint inhibitor treatment
Tina Krieger, Isobel Pearson, Judith A. Bell, et al.
Diagnostic Pathology (2020) Vol. 15, Iss. 1
Open Access | Times Cited: 53
Extracellular vesicle PD-L1 in reshaping tumor immune microenvironment: biological function and potential therapy strategies
Jiaxing Liu, Xueqiang Peng, Shuo Yang, et al.
Cell Communication and Signaling (2022) Vol. 20, Iss. 1
Open Access | Times Cited: 34
Clinicopathological values of PD-L1 expression in HER2-positive breast cancer
Sasagu Kurozumi, Kenichi Inoue, Hiroshi Matsumoto, et al.
Scientific Reports (2019) Vol. 9, Iss. 1
Open Access | Times Cited: 46
Page 1 - Next Page

Scroll to top